Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Revisit NIH biosafety guidelines.

Oye KA, O'Leary M, Riley MF.

Science. 2017 Aug 18;357(6352):627. doi: 10.1126/science.aao6398. No abstract available.

PMID:
28818918
2.

Pharmaceuticals Licensing and Reimbursement in the European Union, United States, and Japan.

Oye KA, Eichler HG, Hoos A, Mori Y, Mullin TM, Pearson M.

Clin Pharmacol Ther. 2016 Dec;100(6):626-632. doi: 10.1002/cpt.505. Epub 2016 Oct 17.

PMID:
27618128
3.

The next frontier: Fostering innovation by improving health data access and utilization.

Oye KA, Jain G, Amador M, Arnaout R, Brown JS, Crown W, Ferguson J, Pezalla E, Rassen JA, Selker HP, Trusheim M, Hirsch G.

Clin Pharmacol Ther. 2015 Nov;98(5):514-21. doi: 10.1002/cpt.191. Epub 2015 Sep 10. Review. No abstract available.

4.

Drugs: Regulate 'home-brew' opiates.

Oye KA, Lawson JC, Bubela T.

Nature. 2015 May 21;521(7552):281-3. doi: 10.1038/521281a. No abstract available.

PMID:
25993942
5.

Gene drives raise dual-use concerns--response.

Oye KA, Esvelt KM.

Science. 2014 Aug 29;345(6200):1010-1. doi: 10.1126/science.345.6200.1010-c. No abstract available.

PMID:
25170143
6.

Biotechnology. Regulating gene drives.

Oye KA, Esvelt K, Appleton E, Catteruccia F, Church G, Kuiken T, Lightfoot SB, McNamara J, Smidler A, Collins JP.

Science. 2014 Aug 8;345(6197):626-8. doi: 10.1126/science.1254287. Epub 2014 Jul 17. No abstract available.

PMID:
25035410
7.

A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials.

Selker HP, Oye KA, Eichler HG, Stockbridge NL, Mehta CR, Kaitin KI, McElwee NE, Honig PK, Erban JK, D'Agostino RB.

Clin Pharmacol Ther. 2014 Feb;95(2):147-53. doi: 10.1038/clpt.2013.177. Epub 2013 Sep 23.

8.

What rough beast?

Mukunda G, Oye KA, Mohr SC.

Politics Life Sci. 2009 Sep;28(2):2-26. doi: 10.2990/28_2_2.

PMID:
20205520

Supplemental Content

Support Center